High-Resistance IMST for Blood Pressure: What We Know

Five minutes of hard breathing per day lowered systolic blood pressure by about 9 mmHg in a small, double-blind randomized trial. That result deserves attention: a change of that size can matter clinically. It also deserves restraint. The finding comes from 36 people, six weeks of training, and one research group. High-resistance inspiratory muscle strength training (IMST) looks promising as an adjunct for elevated blood pressure, not as a reason to throw away your walking shoes or alter prescribed medication.

What the main trial found

In a 2021 randomized, double-blind, sham-controlled trial, 36 adults ages 50 to 79 with systolic blood pressure of at least 120 mmHg used an electronically calibrated POWERbreathe K3 device for six weeks. The active group performed 30 resisted breaths per session at 75% of maximal inspiratory pressure (PImax). The sham group trained at 15% PImax, a load intended to provide little physiological stimulus.

The active protocol took roughly five minutes a day and reduced casual systolic blood pressure by about 9 mmHg versus sham control; the between-group result was statistically significant at p<0.05. The study did not establish how large the average effect would be in the general population. With only 36 participants, its confidence intervals were wide, so the true effect could be smaller or larger than the headline number.

The same trial found an approximately 45% improvement in brachial artery flow-mediated dilation (FMD) versus sham. FMD measures how well a conduit artery dilates in response to increased blood flow. It is a validated marker of endothelial function, but it is still a surrogate outcome. The trial did not show fewer strokes, heart attacks, kidney events, or deaths.

The useful claim is narrow: high-resistance IMST lowered systolic blood pressure and improved an endothelial-function marker over six weeks in older adults with above-normal blood pressure. Claims about long-term cardiovascular protection go beyond the evidence.

This is strength training for breathing muscles, not slow breathing

IMST is often confused with relaxation breathing or device-guided slow breathing. The intervention in the trial imposed a high inspiratory load: participants had to pull air through calibrated resistance. The practical protocol used 30 breaths as five sets of six breaths, with one minute of rest between sets, six days per week. Resistance progressed from 55% to 65% to 75% PImax, with weekly PImax reassessment.

The investigators tested a possible biological explanation by exposing cultured human endothelial cells to serum collected after training. Those cells showed greater nitric oxide bioavailability, greater eNOS phosphorylation at Ser1177, and lower reactive oxygen species. Participants also had lower systemic vascular resistance without a heart-rate change, which fits peripheral vasodilation. These experiments support a circulating-factor hypothesis; they do not directly measure eNOS activity or nitric oxide flux in a living person during IMST.

A 2023 sham-controlled trial of device-guided slow breathing found changes in post-meal oxidative stress in young adult men. That intervention uses respiratory and autonomic entrainment rather than heavy inspiratory loading. Similar-sounding breathing devices can therefore work through different pathways and should not be treated as interchangeable.

How does the blood-pressure result compare with exercise?

The time burden is the striking part. A 2022 randomized comparison in postmenopausal women with above-normal systolic pressure reported comparable blood-pressure improvements from IMST and standard aerobic exercise, which required about 150 minutes a week. It is the only published direct comparison of these approaches in this literature, and it came from the same Colorado research group as the main trial. It shows that the result can recur within that group; it does not provide independent replication.

Indirect comparisons offer context, not a winner. A 2021 meta-analysis of interval and moderate-intensity continuous exercise reported systolic-pressure reductions of roughly 4 to 8 mmHg in cardiovascular-risk populations. A 2024 meta-analysis also found that exercise improved FMD in people with hypertension. Those estimates draw on much larger and more varied bodies of research than the IMST trial, so confidence in exercise does not rest on a single 36-person study.

Dietary nitrate provides another nitric-oxide-related benchmark. A 2025 GRADE-assessed meta-analysis estimated systolic-pressure reductions of about 2 to 4 mmHg with dietary nitrate in randomized trials. In a separate eight-week trial, beetroot juice containing nitrate and nitrite reduced peripheral systolic pressure in people with type 2 diabetes, while the depleted placebo did not Bock et al., 2022. Nitrate increases nitric-oxide availability through an exogenous substrate route; that does not prove IMST produces its effect through the same route.

What else supports—and limits—the idea

High-resistance IMST may affect more than arm-artery FMD. A 2023 randomized trial in midlife and older adults found increased cerebrovascular reactivity after the same general high-resistance paradigm. Cerebrovascular reactivity measures how cerebral vessels respond to vasoactive stimuli. It is relevant to vascular aging, but it is not evidence that IMST prevents cognitive decline or stroke.

A 2024 systematic review of inspiratory muscle training in older adults found cardiorespiratory benefits across the broader IMT literature. The protocols varied substantially, including lower-resistance approaches that are not equivalent to training at 75% PImax. The review provides biological context, not confirmation that every inspiratory trainer can lower blood pressure by 9 mmHg.

Other exercise studies also show why vascular endpoints should not be lumped together. In hypertensive patients, eight weeks of walking-based high-intensity interval training improved microvascular function but not macrovascular FMD in a 2023 randomized study. Different interventions, vascular beds, populations, and durations can produce different results. A favorable FMD result in one trial is meaningful, but it is not a universal cardiovascular scorecard.

The gaps matter more than the gadget

All completed published randomized outcome trials of this specific high-resistance protocol come from one research group. No peer-reviewed outcomes from independent trials in higher-risk populations, obstructive sleep apnea, or type 2 diabetes have yet confirmed the effect. That creates a real risk that the first estimate is too optimistic, even though the original study used a strong sham-controlled design.

Durability is also uncertain. In the 2021 trial, participants who completed an optional six-week post-training follow-up retained about 75% of the blood-pressure benefit. Some detraining occurred within six weeks, and no published data extend beyond 12 weeks after stopping. A maintenance plan will probably be necessary, but no study has established the minimum effective frequency.

Finally, the session itself is not physiologically gentle. A 2021 acute study in healthy young adults recorded transient cardiovascular excitation during one high-intensity IMST session. People with uncontrolled hypertension, aortic aneurysm or other aortic disease, severe aortic stenosis, or a recent cardiovascular event should seek medical clearance before trying it. Those groups were not adequately studied in the completed trials.

A practical verdict

For an adult with systolic pressure in the 120 to 139 mmHg range, high-resistance IMST is a reasonable low-time adjunct to discuss with a clinician—especially when mobility or schedule makes conventional exercise hard to sustain. Use a device that can measure PImax and adjust resistance. Fixed-resistance consumer tubes have not been validated as equivalents to the electronically calibrated protocol.

Keep the hierarchy straight. The evidence supports a six-week blood-pressure signal, not a replacement for antihypertensive treatment, aerobic exercise, or broader cardiovascular care. If independent trials reproduce a similar effect and establish a maintenance dose, IMST could become a useful addition to routine blood-pressure management. Until then, it is an intriguing tool with a small but well-designed first trial behind it.